Covering: Biology - Neuroscience - MedicineCovering: Biology - Neuroscience - Medicine
All explained papers

New England Journal of Medicine, 2026 Aug 13 · 7 min read

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica

There is a rheumatic disease that mostly affects people over fifty. It causes severe shoulder and hip pain that comes on within weeks, and for decades it has been treated with one drug: prednisone. Prednisone works quickly and dramatically, but long-term use brings serious side effects, and the disease often comes back when the dose is lowered. A phase 3 trial in the New England Journal of Medicine, first posted online in June, tests a targeted therapy that may offer a way to spare or replace steroids for the first time.

The disease is polymyalgia rheumatica, or PMR. It is an inflammatory condition that brings aching and stiffness to the shoulders, neck, upper arms, hips, and thighs. It usually develops over days to weeks, often in people over sixty-five. Morning stiffness is the hallmark: people describe trouble getting out of bed or raising their arms above their heads. Blood tests show raised markers of inflammation, the erythrocyte sedimentation rate and C-reactive protein. The name says what it is: pain in many muscles, from a rheumatic, inflammatory cause.

Doctors recognise PMR by its pattern. It hits the large joints and muscles close to the body's centre, the shoulders and hips, not the hands and feet as rheumatoid arthritis does. It starts fairly fast, and the inflammation markers are high. The response to prednisone is often so quick and so dramatic that it counts as part of the diagnosis: if someone with the right features starts prednisone and improves within days, that supports the call.

What causes PMR is not well established. It is linked to giant cell arteritis, a related inflammation of large blood vessels, and the two overlap. Whether they are one disease at different points on a spectrum or two diseases that share machinery is still debated. The immune cells involved are those tied to interleukin-17, one of the key signalling molecules in autoimmune disease. That is the biological reason for the drug in this trial.

The drug is secukinumab, a monoclonal antibody that blocks interleukin-17A, or IL-17A. A monoclonal antibody is an engineered protein built to grab one specific target with high precision and switch it off. IL-17A is a cytokine, a small protein the immune system uses as a messenger. In several inflammatory diseases it tells the body to make more inflammatory molecules and to call immune cells to the scene. Secukinumab is already approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis, all diseases where IL-17A plays a central role. The idea for PMR is that a similar IL-17-driven loop keeps the inflammation going.

So why look beyond prednisone? Prednisone is a corticosteroid, a broad anti-inflammatory that turns down the immune system along many pathways at once. Think of it as a blunt instrument: it works, but it hits everything nearby. Most people with PMR feel dramatic relief within forty-eight to seventy-two hours. But long-term steroid use brings bone loss leading to osteoporosis and fractures, high blood sugar and new diabetes, weight gain, high blood pressure, immune suppression that raises infection risk, thin skin, and cataracts. People who get PMR are over sixty and already at higher baseline risk for these problems, so the harms stack up.

And the treatment tends to drag on. PMR often needs steroids for one to two years or longer. Lowering the dose frequently triggers a relapse, and a relapse means going back up to a higher dose, which stretches the exposure further. Over time the total steroid load can be large. That is why the field has hunted for steroid-sparing strategies: treatments that allow lower doses, or that treat the disease without steroids at all.

The link to giant cell arteritis matters here. That disease inflames large and medium blood vessels, especially the temporal artery in the scalp and the arteries that feed the eyes. It can cause headache, scalp tenderness, and in serious cases vision loss or stroke. It hits the same age group, uses similar inflammatory pathways, and roughly fifteen to thirty percent of people with PMR also have it. Some researchers see a spectrum, with PMR at one end, giant cell arteritis at the other, and some patients having both. The difference matters because giant cell arteritis carries the risk of blindness and needs aggressive treatment.

Another targeted drug, tocilizumab, blocks the receptor for interleukin-6. It is approved for giant cell arteritis and has been studied in PMR, where it has shown some steroid-sparing benefit. But that evidence is smaller, and its standing in PMR is not as established. Related diseases are not identical, and a drug that works in one does not automatically work in the other. Secukinumab takes a different route, aiming at IL-17A instead of IL-6, which is why it needed its own trial.

A phase 3 PMR trial typically enrols people who are newly diagnosed or whose disease keeps relapsing, either just starting steroids or stuck on a dose that cannot be lowered. One group adds the new drug, the other adds a placebo, and both continue some background steroid plan. The main measure is usually the share of patients in remission at a set time, or the total prednisone dose over the trial, which answers the steroid-sparing question directly. These trials are hard to run, because prednisone works so well that patients improve whichever group they are in. That shrinks the difference a trial can detect.

What did this trial find? This account is based on the published abstract; the full text is behind a paywall. The trial compared secukinumab with placebo in people with PMR, in a design that tested whether the drug allowed steroid reduction, improved disease control, or cut relapses. The main reported finding is a significant benefit in the secukinumab group. The exact endpoint, the size of the effect, and the detailed safety record are in the full text, which was not available.

How much weight should the result carry? A phase 3 randomised controlled trial in this journal sits at the top tier of clinical evidence, and its peer review is extensive. Phase 3 also means earlier phases showed safety and early signs of benefit, and this trial was designed to confirm efficacy in a larger group with a main endpoint fixed in advance. The confidence interval and effect size cannot be judged precisely from the abstract alone, but the design and venue are strong signals. Independent replication would be the next step before guidelines change.

If the drug works, it would give doctors a targeted way to cut steroid exposure in PMR. The ideal plan lets secukinumab carry the anti-inflammatory load while prednisone is tapered faster or to a lower maintenance dose. People with PMR are older and often have several other conditions that make steroid side effects especially dangerous. Avoiding a fracture from osteoporosis, or not pushing someone with borderline blood sugar into diabetes, would be a real advance even without a cure.

Blocking IL-17A has its own risks. IL-17A helps defend the body's surfaces, the gut, lungs, and skin. Blocking it long-term raises the chance of certain fungal infections, especially Candida, and may worsen inflammatory bowel disease; secukinumab should not be used in people with active inflammatory bowel disease. These risks are known from the approved uses. In an older PMR population, many with several conditions, they must be weighed against the steroid risks being avoided. It is not a free swap, though the balance may favour the targeted drug for many patients.

The bigger picture is a shift across rheumatology. For most of the twentieth century, inflammatory diseases were treated with broad immune suppressants: corticosteroids, methotrexate, azathioprine. The biologic era, starting in the late 1990s with the first TNF blockers for rheumatoid arthritis, introduced the idea of blocking one specific messenger or receptor in one specific disease. PMR was one of the last major rheumatic conditions still relying almost entirely on the blunt instrument. If secukinumab holds up, it brings PMR into the precision era.

It also reframes PMR as a disease worth its own drug pipeline, not just steroid management. For a long time it was treated as manageable rather than targetable, because steroids suppressed symptoms well enough that the field did not invest much in its specific mechanisms. With better IL-17 biology, better trial infrastructure, and patients willing to enrol, the mechanistic work is catching up with the clinical need.

Cost is a real barrier. Monoclonal antibodies like secukinumab are expensive, and prednisone is very cheap, which matters in a disease of older people on fixed incomes. The counterpoint from health economists is that steroid complications, such as hip fractures, diabetes care, and hospital stays for infections, are also costly and often fall on the same patients and payers. Whether the net cost is favourable depends on how the trial's benefit turns into fewer steroid complications in real life. Insurers and health technology assessment bodies in each country will make that call before deciding coverage.

The paper is PMID 42234540, published in the New England Journal of Medicine on August 13, 2026, first posted online in June 2026; this account is based on the abstract, as the full text is behind a paywall.